We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. government is planning to launch phase 3 trials of three COVID-19 vaccine candidates, starting with Moderna’s as soon as next month, followed by AstraZeneca’s AZD1222 in August, and a Johnson & Johnson candidate in September. Read More
Aimmune Therapeutics said that 80 percent of allergic patients in a trial of its oral immunotherapy Palforzia (peanut allergen powder-dnfp) were desensitized to peanut proteins. Read More
AstraZeneca has licensed six monoclonal antibodies from Vanderbilt University and plans to advance the most promising ones for prevention and treatment of COVID-19. Read More
Regeneron Pharmaceuticals and Vir Biotechnology said they will soon begin clinical trials of monoclonal antibodies they hope will be able to prevent or treat COVID-19 patients. Read More
Results from preliminary research show that AstraZeneca’s blood cancer treatment Calquence (acalabrutinib) provides a benefit in hospitalized COVID-19 patients. Read More